BEVACIZUMAB TNJN

N/A

Manufactured by Bio-Thera Solutions, Ltd.

59 FDA adverse event reports analyzed

Last updated: 2026-04-15

About BEVACIZUMAB TNJN

BEVACIZUMAB TNJN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Bio-Thera Solutions, Ltd.. The most commonly reported adverse reactions for BEVACIZUMAB TNJN include HEPATIC FUNCTION ABNORMAL, MYELOSUPPRESSION, ASTHENIA, NAUSEA, PLATELET COUNT DECREASED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BEVACIZUMAB TNJN.

Top Adverse Reactions

HEPATIC FUNCTION ABNORMAL6 reports
MYELOSUPPRESSION6 reports
ASTHENIA3 reports
NAUSEA3 reports
PLATELET COUNT DECREASED3 reports
WHITE BLOOD CELL COUNT DECREASED3 reports
DYSPHAGIA2 reports
GINGIVAL BLEEDING2 reports
PRODUCT USE IN UNAPPROVED INDICATION2 reports
VOMITING2 reports
ALANINE AMINOTRANSFERASE INCREASED1 reports
ANGINA PECTORIS1 reports
APLASTIC ANAEMIA1 reports
ASCITES1 reports
BLOOD POTASSIUM INCREASED1 reports
BLOOD PRESSURE DECREASED1 reports
COAGULOPATHY1 reports
DECREASED APPETITE1 reports
DIARRHOEA1 reports
DRUG INDUCED LIVER INJURY1 reports
ELECTROCARDIOGRAM T WAVE PEAKED1 reports
GAIT DISTURBANCE1 reports
HAEMATURIA1 reports
HEPATIC FAILURE1 reports
IMMUNE THROMBOCYTOPENIA1 reports
INTERSTITIAL LUNG DISEASE1 reports
LIVER INJURY1 reports
MUSCULAR WEAKNESS1 reports
NEUTROPHIL COUNT DECREASED1 reports
PALPITATIONS1 reports
PERICARDIAL EFFUSION1 reports
PLEURAL EFFUSION1 reports
PRODUCT USE ISSUE1 reports
PROTEINURIA1 reports
SUSPECTED DRUG INDUCED LIVER INJURY1 reports
TOXIC EPIDERMAL NECROLYSIS1 reports
URINARY OCCULT BLOOD POSITIVE1 reports

Report Outcomes

Out of 22 classified reports for BEVACIZUMAB TNJN:

Serious 100.0%Non-Serious 0.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male16 (72.7%)
Female6 (27.3%)

Reports by Age

Age 532 reports
Age 582 reports
Age 682 reports
Age 692 reports
Age 742 reports
Age 101 reports
Age 431 reports
Age 471 reports
Age 551 reports
Age 611 reports
Age 631 reports
Age 641 reports
Age 651 reports
Age 661 reports
Age 671 reports
Age 711 reports
Age 731 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with BEVACIZUMAB TNJN?

This profile reflects 59 FDA FAERS reports that mention BEVACIZUMAB TNJN. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for BEVACIZUMAB TNJN?

Frequently reported terms in FAERS include HEPATIC FUNCTION ABNORMAL, MYELOSUPPRESSION, ASTHENIA, NAUSEA, PLATELET COUNT DECREASED, WHITE BLOOD CELL COUNT DECREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures BEVACIZUMAB TNJN?

Labeling and FAERS entries often list Bio-Thera Solutions, Ltd. in connection with BEVACIZUMAB TNJN. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.